Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Acorda Therapeutics logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.66
$15.60
52-Week Range
N/A
Volume
416,900 shs
Average Volume
119,299 shs
Market Capitalization
$820,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Remove Ads
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Acorda: I did not accept money from Guo
See More Headlines

ACOR Stock Analysis - Frequently Asked Questions

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, topping analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.

Acorda Therapeutics's stock reverse split on the morning of Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acorda Therapeutics investors own include Meta Platforms (META), Sangamo Therapeutics (SGMO), General Electric (GE), NVIDIA (NVDA), Exxon Mobil (XOM), Energy Transfer (ET) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
11/09/2021
Today
4/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
Employees
111
Year Founded
1995

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-252,850,000.00
Net Margins
-214.95%
Pretax Margin
-251.65%

Debt

Sales & Book Value

Annual Sales
$117.63 million
Price / Cash Flow
0.02
Book Value
($127.17) per share
Price / Book
N/A

Miscellaneous

Free Float
1,210,000
Market Cap
$820,000.00
Optionable
No Data
Beta
1.40

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:ACOR) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners